Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

BURLINGTON, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
September 01, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

BURLINGTON, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
August 09, 2022 07:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance commercial readiness activities in support of...
July 13, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion

BURLINGTON, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
July 12, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure

Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints FUROSCIX demonstrated an acceptable tolerability profile Company on track for Q4...
June 30, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients

BURLINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
June 07, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting

BURLINGTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
May 24, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Present at the Jefferies Healthcare Conference

BURLINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
May 17, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

BURLINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
May 16, 2022 07:10 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

FDA assigns PDUFA action date of October 8, 2022 Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved Ended Q1 with cash, cash...